Goal 2: Reduce Human Disease

To extend our knowledge of the pathobiology of heart, lung, blood, and sleep disorders and enable clinical investigations that advance the prediction, prevention, preemption, treatment, and cures of human disease.
(@nhlbiforumadministrator)

Goal 2: Reduce Human Disease

Study of Prevention of Airflow Obstruction Progression

There should be a study for prevention of Airflow Obstruction Progression. Rationale: All diseases have a prodrome followed by an early face of disease progression. Complex medical chronic diseases can only be slowed through the addition of several interventions all of which contribute to a final improvement of prognosis (witness CV diseases). Definition of “Early Disease”: Would be aimed at patients with airflow obstruction... more »

Voting

1 net vote
1 up votes
0 down votes
Active
(@nhlbiforumadministrator)

Goal 2: Reduce Human Disease

Understanding Pathobiology of Exacerbations

COPD exacerbations contribute to poor quality of life, lung function and functional decline. In addition, they are costly to the patient and to health care cost. However, they remain defined exclusively on symptoms and constitute a “soft” endpoint. Actually, the number of exacerbations has become the GOLD standard to establish the risk of outcome (exacerbations). However, a mild episode that only requires outpatient... more »

Voting

1 net vote
1 up votes
0 down votes
Active
(@nhlbiforumadministrator)

Goal 2: Reduce Human Disease

Clinicial studies of Azithromycin for COPD Treatment

Azithromycin is very effective at reducing exacerbations in COPD, but we do not understand the biological mechanism, i.e. anitbiotic effect versus antiinflammatory effect. Because we do not understand how it works (and because of the potential for side effects), azithromycin is not yet widely used. Clinical studies designed to answer this question would help us refine our therapeutic approach and may allow us to minimze... more »

Voting

3 net votes
3 up votes
0 down votes
Active
(@nhlbiforumadministrator)

Goal 2: Reduce Human Disease

Lung Transplantation

As in other solid organ transplants, adherence to the medical regimen after adult and pediatric lung transplantation is less than ideal and contributes to poor health outcomes. a) How can we improve the prediction of which lung transplant recipients are at greatest risk for nonadherence? b) What are the most efficient and effective ways of assessing nonadherence in the clinical setting? c) Conduct clinical trials of... more »

Voting

1 net vote
1 up votes
0 down votes
Active
(@nhlbiforumadministrator)

Goal 2: Reduce Human Disease

Lung Transplantation

Although the majority of lung recipients experience significant health improvement, they also frequently face serious symptom distress, impaired physical functioning and poor quality of life due to post-transplant morbidity, such as chronic rejection, infection and multiple side-effects of immunosuppression. a) Conduct clinical trials of interventions designed to maximize clinicians' support of patients' self-management... more »

Voting

1 net vote
1 up votes
0 down votes
Active